Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment

Physician perceptions and use of reduced‐dose direct oral anticoagulants for extended phase venous thromboembolism treatment

Abstract Background The direct oral anticoagulants (DOACs), apixaban and rivaroxaban, have been studied for extended‐phase treatment of venous thromboembolism (VTE). Yet, scant evidence exists surrounding clinician practice and decision‐making regarding dose reduction. Aims Report clinician practice...

Full description

Bibliographic Details
Main Authors: Danielle Groat, Karlyn A. Martin, Rachel P. Rosovsky, Kristen M. Sanfilippo, Manila Gaddh, Lisa Baumann Kreuziger, M. Elaine Eyster, Scott C. Woller, for the Venous thromboEmbolism Network US (VENUS) VTE Treatment, Anticoagulation Management Group
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
anticoagulant
apixaban
reduced‐dose
rivaroxaban
treatment
venous thromboembolism
Online Access:https://doi.org/10.1002/rth2.12740

Internet

https://doi.org/10.1002/rth2.12740

Similar Items